The Phase 1 trial, sponsored by The Methodist Hospital Research Institute, investigates the safety and tolerability of a combination therapy involving abatacept (Orencia) and subcutaneous IL-2 in ALS patients. Given the urgent need for effective treatments in ALS, which currently has limited therapeutic options, this trial could position the sponsor favorably within the niche ALS market. If successful, the findings may lead to further development and potential commercialization of this combination therapy, addressing a significant unmet medical need. Competitive implications include potential partnerships or licensing opportunities, particularly with companies focused on immunotherapy and neurodegenerative diseases. Diligence should focus on regulatory pathways and reimbursement strategies for ALS therapies.